Relatlimab

Relatlimab
Monoclonal antibody
TypeWhole antibody
SourceHuman
TargetLAG3
Clinical data
Other namesBMS-986016
ATC code
  • none
Identifiers
CAS Number
UNII
KEGG
Chemical and physical data
FormulaC6472H9922N1710O2024S38
Molar mass145288.79 g·mol−1

https://www.nejm.org/doi/10.1056/NEJMoa2109970

Relatlimab (INN; development code BMS-986016) is a monoclonal antibody designed for the treatment of melanoma.[1][2][3][4]

This drug is being developed by Bristol-Myers Squibb. As of 2018, relatlimab is undergoing Phase II/III trials.[5]

References

  1. Statement On A Nonproprietary Name Adopted By The USAN Council - Relatlimab, American Medical Association.
  2. World Health Organization (2018). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 119" (PDF). WHO Drug Information. 32 (2).
  3. Cavagnaro JA, Cosenza ME, eds. (2021). Translational Medicine: Optimizing Preclinical Safety Evaluation of Biopharmaceuticals. Boca Raton, Florida: CRC Press. ISBN 978-1-00-047185-4.
  4. Robert C (December 2021). "LAG-3 and PD-1 blockade raises the bar for melanoma". Nature Cancer. 2 (12): 1251–3. doi:10.1038/s43018-021-00276-8.
  5. Clinical trial number NCT03704077 for "An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Therapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma" at ClinicalTrials.gov
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.